Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Inclusion Criteria:

• Patients with radiologically or histologically confirmed postoperative RecurrentPancreatic Cancer
• Patients with at least one measurable lesion (according to RECIST 1.1 criteria);
• Have not received gemcitabine-based regimen after surgery
• No systemic treatment after diagnosis of recurrence
• ECOG score 0-1
• Expected survival ≥ 3 months;
• Liver function is essentially normal: absolute neutrophil count > 1500/mm ³; plateletcount > 100,000/mm ³; creatinine less than 1.5 times the upper limit of normal orcalculated creatinine clearance (CRCI) > 45 mL/min; total bilirubin ≤ 2.0 mg/dL;aspartate aminotransferase (AST) and alanine aminotransferase less than 2.5 times theupper limit of normal
• Appropriate to participate in this trial as assessed by the investigator beforeentering the study
• Male and female subjects of childbearing potential must agree to use an effectivemethod of contraception throughout the study
• Signed Informed Consent Form

Exclusion Criteria:

• Patients who only undergo abdominal laparotomy but do not undergo resection ofpancreatic tumor tissue
• Received gemcitabine-based regimen after surgery
• Systemic treatment after diagnosis of recurrence
• Patients with previous allergic reactions to similar drugs
• Pregnant or lactating patients
• Presence of pericardial effusion, uncontrolled pleural effusion, or clinicallysignificant ascites at screening (including detectable ascites or ascites requiringpuncture and aspiration on physical examination at screening)
• History of interstitial lung disease, pneumonitis, or uncontrolled systemic disease,including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc
• Patients with severe cardiovascular diseases within 12 months before enrollment, suchas symptomatic coronary heart disease, ≥ grade II congestive heart failure,uncontrolled arrhythmia, myocardial infarction, etc
• Presence of any active immunodeficiency or autoimmune disease and/or history of anyimmunodeficiency or autoimmune disease that may recur at screening (e.g.,hypothyroidism or hyperthyroidism, interstitial pneumonia, enteritis, hepatitis,hypophysitis, vasculitis, myocarditis, etc)
• Use of steroids or other systemic immunosuppressive therapy 14 days prior toenrollment
• Patients with other previous malignancies who are not cured
• Immunodeficient patients, such as HIV-positive
• Uncontrollable psychosis